#Short Bowel Syndrome Pipeline Drugs Market | Explore Tumblr Posts and Blogs

pharmaphorumuk · 5 years

Text

UK leaders: Takeda’s Jon Neal

In the first of a new series where we talk to GMs of UK pharma divisions, managing director for Takeda UK & Ireland, Jon Neal, tells us about the Shire acquisition, rare diseases, and access challenges in the region.

How did you get into the UK & Ireland managing director role?

I joined Takeda 10 years ago as their marketing director for the UK. I went on to have three different business unit head roles, and I was behind the launch of Entyvio in the country. After that I took over the oncology division and led the launches of cancer drugs.

I took over the managing directing role in April 2018, just before we announced the acquisition of Shire. I’ve since been running the integration of the two companies in the UK, while trying to maintain the momentum in both organisations’ businesses and pull them together into a new Takeda in the UK and Ireland.

Did you have any particular goals when you came into the role, and have they changed in light of the Shire acquisition?

I took over the managing director role when Takeda was doing well in terms of results and, after previously being a company where each country ran fairly independently, was rolling out more global systems and processes. My main goal was to maintain that momentum and take us to that next level – from a small-to-medium company to a medium-large organisation.

“There are thriving ecosystems here, and it’s really about getting alignment with other stakeholders on what the challenges are, then trying to work collaboratively, in a very open and transparent way”

That got turned on its head three months into my tenure when the company announced that it was going to acquire Shire. The acquisition essentially doubles our scale and complexity and makes us the ninth biggest pharma company in the world – and the 11th biggest company in the UK market. It has transformed our profile and the range of diseases that we make medicines for; we’re now present in neuroscience and rare diseases, for example.

Since then I’ve aimed to complete the integration as effectively and rapidly as possible while maintaining our culture and values – such as our focus on the patient, and on how we build trust with external stakeholders. Our ethos is that if you have a patient focus, develop trust and build your reputation, ultimately it will lead to sustainable growth for your company, and you’ll also help the sustainability of the health systems that we all rely on.

That culture was non-negotiable during the integration, so a large part of my job has been making sure that it is embedded in the UK – as the UK entity is perceived within Takeda as being at the forefront of those values – whilst maintaining our external momentum. Often when companies go through integrations everybody starts to look inwards, because they’re worried about what new processes and structures they’re going to have, and I really wanted to avoid that.

Rare diseases can be quite different from other therapy areas – how have you had to adapt to that after acquiring Shire?

I’m a big believer that the more disease areas you work in the easier it is to pick up the next one, a bit like languages. That diversity is something that we’re really embracing.

It has been fascinating for me over the last 12 months to learn about conditions like Hunter syndrome, Gaucher’s disease, and short bowel syndrome – and that’s even before we started looking at the pipelines. I’ve had the chance to meet a lot of the clinicians, patient groups and external stakeholders involved in these diseases – I’ve focused on meeting a lot of them personally, but also tying myself and the members of our leadership team into those areas so that we can get up to speed as quickly as possible. Shire had a really strong focus on policy work, and that’s something we want to continue.

For example, one of the rare disease spaces we work in is immunoglobulin products. There’s a shortage of plasma-derived therapies in the area, but a surge in the demand for them globally. Plasma collection was stopped in the UK as a precautionary measure many years ago, and we’re actively engaging with government to see if we can develop a more sustainable supply chain for these products.

What are some of the biggest challenges in rare diseases you’re hoping to tackle?

In many rare diseases there are two big issues: getting to a diagnosis and being able to get appropriate treatment. Treatment is not just medicine. Treatment could be multi-dimensional.

We’re currently working with EURORDIS – The Voice of Rare Disease Patients in Europe – and Microsoft to see how we can embrace the use of technology to help speed up diagnosis for some rare diseases. Diagnosis can sometimes take over ten years, because GPs may only see one of these cases in their entire career, and will therefore never be able to spot the patterns that would flag a patient. With machine learning, though, we can potentially spot those patterns in patients’ symptomatology and intelligently flag people that should be screened. We have a couple of pilots in that area ongoing in the UK at the moment, looking at cohorts of data with specific hospitals.

There are great opportunities to collaborate with the NHS here to help improve diagnostics and make sure we can track the value of our medicines and the outcomes for patients. I think that’s an area where we will see huge developments over the next few years.

Would you say you’re generally quite positive about the future of the UK environment?

I think the biggest challenge we face is in the access arena and making sure that the UK continues to be a country that gets the most innovative medicines to patients as soon as possible. That’s an ongoing challenge. Organisations like NICE have a great international reputation, and things like the Institute’s method review over the next 12 months are crucial to making sure it continues to evolve.

One of the areas we really need to focus on is getting innovative medicines to patients in an appropriate and sustainable way for the NHS to move forward. At the moment there are a huge number of medicines that have life-changing potential coming through the pipeline, and we’ve got to make sure we can find ways of getting them to patients.

Things like interim access are really important for that. We’ve had interim access in oncology in the UK for a number of years through the Cancer Drugs Fund, but there are other diseases that have an equally devastating impact on patients’ lives that lack a way of getting access to medicines while the evidence base is growing. We need to find a way of doing that. The Conservative Party manifesto promised a move away from the Cancer Drugs Fund towards an ‘Innovative Medicine Fund’. I think that’s something Takeda and a lot of other companies would welcome.

I think the UK has always had an incredibly collaborative system. I’ve always felt that the power of patient groups in the UK is probably second to none in terms of their sophistication and their influence, and the difference they’ve made to patients’ lives. Meanwhile, if the NHS sees your intentions as pure you can collaborate very well with them.

In the UK we’ve got some of the world’s best senior leaders, some of the most influential patient groups, and some of the best universities. There are thriving ecosystems here, but it’s really about finding areas of unmet need and getting alignment with other stakeholders on what the challenges are, then trying to work collaboratively, in a very open and transparent way, so that we all know what everybody’s intentions are. You need to make sure that you’re listening very hard to those you collaborate with so you can find out what the challenges are and help them with solutions.

What are your ambitions for the combined company over the next few years?

We have an aspiration to be a leading company within the specialty and rare disease context. We want to work collaboratively with the health system to not just ensure rapid and broad access to medicines but also to help transform outcomes. When we were a medium-sized company we had a lot of agility, and we really want to retain that now that we’re a bigger organisation.

I’d like to see Takeda UK and Ireland break into the top 10 companies in the region over the next few years, and also for us to be recognised within Takeda itself as one of the most forward thinking and innovative subsidiaries – one that not only gets good business results but also is regarded externally and internally as highly innovative.

The post UK leaders: Takeda’s Jon Neal appeared first on .

from https://pharmaphorum.com/views-analysis-market-access/uk-leaders-takeda-jon-neal/

0 notes

market-insider · 4 years

Text

North America Opioid Market To Reach $18.5 Billion By 2024

The North America opioid market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, conducive for research and development as well as commercialization efforts directed toward the development of novel abuse-deterrent opioids, to flourish and drive the industry growth during the forecast period. Furthermore, the key players are deploying large funds in the development of abuse-deterrent technology wherein drugs are designed to be tamper resistant. This is achieved through alterations involving, among others, the use of physical or chemical barriers to resist convenient extraction of the opioids, the addition of an aversive agent to the formulation that would yield an unpleasant effect upon its extraction, and the formulation of opioid prodrugs that are dependent on enzymatic activity in order to be rendered to their active forms. These tamper-resistant opioid drug forms are anticipated to mitigate the incidence of their misuse.

Opioids are the mainstay of chronic pain management that is used to alleviate varied pain conditions. Opiates including codeine and morphine are frequently employed as cough suppression medication. Codeine is considered as a gold standard for cough suppression since it has minimal side effects. Moreover, these narcoticsare used in the treatment of irritable bowel syndrome-induced diarrhea since they act on gastrointestinal receptors. In addition, peripherally acting loperamide is commonly used to suppress diarrhea. Thus, theprofitable growth of the Opioid Market lies in its breadth of applications in the management of diverse conditions including cough, diarrhea, and pain.

For More Details Please Visit @: http://www.grandviewresearch.com/industry-analysis/north-america-opioid-market

Further key findings from the study suggest:

· The extended-release opioids segment accounted for the largest share over 55% in 2015. The dominance of the segment is attributed to the high usage of these drugs for chronic pain management and the development of innovative dosage forms, such as transdermal patches.

· Market share of the immediate-release dosage formsincluding morphine and codeine, is expected to decline owing to the frequent product recalls and severe side effects associated with their use. The segment is estimated to witness a CAGR of around 1.7% over the forecast period.

· In terms of applications, the pain relief segment held the largest market share in 2015 with a revenue generation of over 9.3 billion. The extensive amount of pain caused during chemotherapy and radiotherapy are the primary factors resulting in the increasing incorporation of these drugs in the cancer segment.

· The post-operative pain management segment is expected to be the fastest growing application in the pain relief category.As a result of their high applicability in post- surgical pain management, the rise in number of surgical procedures is expected to fuel the sectorpenetration of opioids in the near future.

· The U.S. region dominated the global Opioid Market with a sizable revenue share in 2015. One of the major determinants is the growing geriatric population with clinically demonstrated susceptibility to terminal conditions, such as rheumatoid arthritis, is positively impacting this vertical.

· In addition, the increasing adoption of opioids for pain management related to trauma and injury cases, in severe and chronic disabling diseases, and in cases of post-surgical pain, is driving the growth of the market in the North America region

· The Canada regional verticalis expected to witnesssignificant growth over the forecast period with a CAGR of over 5.3% due tothe improvinghealthcare infrastructure and the presence of favorable government reforms governing the use of narcoticsin the treatment of both, acute and chronic pain, as well as in the cases of persistent cough and diarrhea. Additionally, the expanding generic drugs market in this region is expected to provide a potential growth platform for the key players in this vertical.

· Some of the leadingplayers in this verticalinclude Pfizer, Inc., Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., Allergan Plc (Actavis), and Egalet Corporation. Extensive research and development endeavors carried out by companies with the aim of expanding their product pipeline are expected to boost the growth of this sector.

Grand View Research has segmented the North America opioids market on the basis of product, application,and region:

North America Opioid Market, product outlook by revenue (USD Million, 2014 - 2024)

· Immediate - release / Short - acting Opioids

o Codeine

o Oxycodone

o Hydrocodone

o Fentanyl

o Morphine

o Hydroxymorphone

o Oxymorphone

o Propoxyphene

o Other IR opioids

· Extended - release / Long - acting Opioids

o Oxycodone

o Hydrocodone

o Methadone

o Fentanyl

o Morphine

o Oxymorphone

o Tapentadol

o Buprenorphine

o Hydromorphone

o Other ER opioids

North America Opioid Market, application outlook by revenue (USD Million, 2014 - 2024)

· Pain Relief

o Cancer Pain

o Post-operative Pain Management

o Low Back Pain

o Orthopedic

o Neuropathic Pain

o Fibromyalgia

· Anesthesia

· Cough Suppression

· Diarrhea suppression

· De - addiction

North America market, regional outlook by revenue (USD Million, 2014 - 2024)

· U.S.

#healthcare #North America Opioid Market

0 notes

rohinic123-blog · 5 years

Text

Pediatric Respiratory Disease Treatment Market to Register Substantial Expansion by 2027

Pediatric Respiratory Disease Treatment Market: Introduction

Rise in global pollution levels have caused the pediatric population to be highly susceptible to a number of respiratory ailments. Pediatric respiratory disorders and symptoms include aerodigestive disorders (recurrent aspiration), asthma, chronic cough, and congenital abnormalities of airway & lung development including tracheobronchomalacia, cystic fibrosis, bronchopulmonary dysplasia (chronic lung disease), primary ciliary dyskinesia, recurrent respiratory infections & pneumonia, respiratory failure & ventilator dependency, sleep-apnea, and wheezing.

Report Overview @ https://www.transparencymarketresearch.com/pediatric-respiratory-disease-treatment-market.html

Key Drivers and Restraints of Global Pediatric Respiratory Disease Treatment Market

Rise in prevalence of respiratory disorders, changing lifestyle habits, progressive increase in obese pediatric population, and surge in awareness about pediatric care are anticipated to increase expenditure on pediatric respiratory disease treatment

Allergic rhinitis is the most common form of non-infectious rhinitis. According to the International Study on Asthma and Allergies in Childhood (ISAAC), prevalence of rhinitis varies between 0.8% and 14.9% in six to seven-year old children and between 1.4% and 39.7% in 13 to 14-year old children. Countries with a very low prevalence include Indonesia, Albania, Romania, Georgia, and Greece. Countries with a very high prevalence include Australia, New Zealand, and the U.K.

Planning To Lay Down Future Strategy? Request Brochure Of Pediatric Respiratory Disease Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75423

Treatment Market Report

Government and non-government organizations focus on campaigns to increase awareness about pediatric health. Several associations and foundations are playing an active role in spreading awareness about various pediatric conditions such as short bowel syndrome, neuroblastoma, leukemia, cancer palliative care, respiratory diseases care, mental health, and neonatal care.

The American Academy of Pediatrics (AAP), Substance Abuse and Mental Health Services Administration (SAMHSA), the Child Health and Development Institute (CHDI), the World Child Cancer, the Indian Cancer Society, and others are engaged in creating awareness among people about pediatric disorders

Asthma Segment to Lead Global Market

The global pediatric respiratory disease treatment market can be segmented based on drug class, disease type, distribution channel, and region

In terms of drug class, the global pediatric respiratory disease treatment market can be divided into anti-inflammatory drugs, bronchodilators, combination drugs, corticosteroid, monoclonal antibodies, and others. The combination drugs segment is expected to witness significant growth during the forecast period due to proven efficacy of these drugs in maintaining these conditions and promising pipeline of upcoming drugs in the segment.

Based on disease type, the global pediatric respiratory disease treatment market can be classified into asthma, cystic fibrosis, bronchiolitis, pneumonia, idiopathic pulmonary fibrosis, tuberculosis, and others. According to recent global statistics by the Global Asthma Network, nearly 334 million people across the world are affected by asthma. Among them, 14% are children and 8.6% are young adults (aged between 18 and 45 years). Prevalence is higher in developed countries than developing ones.

In terms of distribution channel, the global pediatric respiratory disease treatment market can be classified into hospitals & clinics, retail pharmacies, and online pharmacies

Asia Pacific to Offer Lucrative Opportunities in Global Pediatric Respiratory Disease Treatment Market

The global pediatric respiratory disease treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a significant market for pediatric respiratory disease treatment due to strong emphasis on health care development and high health care expenditure.

Asia Pacific is also anticipated to offer lucrative opportunities in the pediatric respiratory disease treatment market. This can be attributed to high patient population, rise in awareness about pediatric care, and increase in focus of public & private organizations in preventing respiratory disorders in the developing countries.

To Obtain All-Inclusive Information On Forecast Analysis Of Pediatric Respiratory Disease Treatment Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75423

Key Players Operating in Global Pediatric Respiratory Disease Treatment Market

Leading players in the global pediatric respiratory disease treatment market are:

AstraZeneca plc

Bayer AG

Boehringer Ingelheim GmbH

F. Hoffmann-La Roche AG

GlaxoSmithKline plc

Merck & Co, Inc.

Novartis AG

Regeneron Pharmaceuticals

More Trending Reports by Transparency Market Research –

Advanced (3D/4D) Visualization Systems Market –

https://www.globenewswire.com/news-release/2019/03/25/1760309/0/en/Advanced-3D-4D-Visualization-Systems-Market-to-be-worth-US-3-2-billion-by-2024-TMR.html

Platelet Rich Plasma & Stem Cell Alopecia Treatment Market –

https://www.globenewswire.com/news-release/2019/03/26/1768442/0/en/Platelet-Rich-Plasma-Stem-Cell-Alopecia-Treatment-Market-to-Reach-US-450-Mn-by-2026-TMR.html

0 notes

azveille · 5 years

Text

Pfizer agrees on $340M upfront to buy Therachon for dwarfism drug

Pfizer is set to pay $340 million (€304 million) upfront to buy Therachon for its treatment for a form of short-limbed dwarfism. The deal commits Pfizer to up to $470 million in additional milestones tied to the advance of the early-phase rare disease drug.

Therachon has emerged as one of the better financed European rare disease biotechs in recent years, pulling in $100 million from investors including Novo Holdings and OrbiMed across its series A and B rounds. The funding has supported work on TA-46, a FGFR3 ligand trap designed to prevent the excessive signalling thought to suppress bone growth in people with achondroplasia.

Limited data are available publicly on the drug, which only began testing in healthy volunteers last year. But Pfizer has seen enough promise in the preclinical and phase 1 results to put together an $810 million financial package and make TA-46 a key part of its plans in pediatric growth disorders.

“Pfizer’s existing research programs for pediatric growth disorders provide a complementary setting for this potential breakthrough therapy,” Pfizer Senior Vice President Seng Cheng said in a statement.

Patients with achondroplasia currently lack pharmacological treatment options, but Therachon is far from the only company trying to address the unmet need. BioMarin’s vosoritide moved into phase 3 in 2017, and a small pool of other companies including Denmark’s Ascendis Pharma are also going after the indication. Ascendis thinks the global achondroplasia market could exceed $1 billion.

Therachon’s pipeline also features a synthetic GLP-2 analog that it picked up in its 2018 takeover of GLyPharma Therapeutic. That drug is in phase 2 development in short bowel syndrome but holds less appeal to Pfizer, leading the Big Pharma to clear Therachon to spin it off to form a new startup. Pfizer Ventures will hold a stake in the startup, but the new company will advance the asset independently.

0 notes

morrisbeck07-blog · 5 years

Text

Short Bowel Syndrome Pipeline Intelligence Market Research Report 2019: Description, Product Development, R&D Activities, Pre-Clinical Studies, Therapeutics Scenario

Short Bowel Syndrome Pipeline Intelligence, 2019 report provides comprehensive Intelligences about pipeline drugs across this Indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Short Bowel Syndrome Pipeline Intelligence.

Highlights and Scope of the Report

Indication Overview:

This section of the report provides comprehensive…

View On WordPress

#Short Bowel Syndrome market research report #Short Bowel Syndrome overview #Short Bowel Syndrome patent analysis #Short Bowel Syndrome pipeline Intelligences 2019 #Short Bowel Syndrome share evolution #Short Bowel Syndrome therapeutic products in clinical stages #Short Bowel Syndrome therapeutic products in non-clinical stages

0 notes

navalvessels · 1 year

Text

Unveiling Market Trends in Short Bowel Syndrome: A Comprehensive Analysis

Understanding Short Bowel Syndrome

Short Bowel Syndrome is a condition characterized by the inability of the small intestine to properly absorb essential nutrients and fluids. It often results from surgical removal of a significant portion of the small intestine due to various reasons, Short Bowel Syndrome Pipeline Drugs Market including trauma or disease. Individuals with SBS often struggle with malnutrition, dehydration, and a reduced quality of life.

The Short Bowel Syndrome Market

Market Growth

The Short Bowel Syndrome market has witnessed notable growth in recent years. This growth can be attributed to several factors, including:

Increased Awareness: Growing awareness among healthcare professionals and patients about SBS has led to early diagnosis and intervention.

Advancements in Therapies: The development of novel therapies and treatment options has expanded the scope of managing SBS effectively.

Supportive Regulatory Environment: Regulatory bodies have shown support for research and development in the field of SBS, encouraging pharmaceutical companies to invest in innovative solutions.

Key Players

Several pharmaceutical and biotechnology companies have played a pivotal role in advancing SBS treatment. Some of the key players in the market include:

Shire (a Takeda company): Known for its commitment to rare diseases, Shire has developed therapies that have significantly improved the quality of life for SBS patients.

NPS Pharmaceuticals: This company has been at the forefront of SBS research, with a focus on developing innovative treatments.

Clinical Trials: Ongoing clinical trials are crucial in testing and refining new therapies for SBS. Stay informed about these trials, as they may offer hope to individuals living with this condition.

Emerging Trends

Personalized Medicine

As our understanding of SBS deepens, there is a growing emphasis on personalized medicine. Tailoring treatment plans to an individual's specific needs and genetic makeup holds great promise in improving outcomes for SBS patients.

Nutritional Support

Nutritional support is a cornerstone of SBS management. Emerging trends in nutritional science are leading to the development of specialized diets and supplements that can enhance nutrient absorption in individuals with SBS. Syndrome pipeline drugs market target insights, download a free report sample

#Short Bowel Syndrome Pipeline Drugs Market

0 notes

globalrketresearchanalysis · 7 years

Text

Formulation Of Opioids Switching From Immediate To Extended - Release Forms Is Expected To Drive North America Opioid Market Till 2024

Browse full research report on North America Opioid Market: www.grandviewresearch.com/industry-analysis/north-america-opioid-market

Further Key findings from the study suggest:

The extended-release opioids segment accounted for the largest share over 55% in 2015. The dominance of the segment is attributed to the high usage of these drugs for chronic pain management and the development of innovative dosage forms, such as transdermal patches.

Market share of the immediate-release dosage formsincluding morphine and codeine, is expected to decline owing to the frequent product recalls and severe side effects associated with their use. The segment is estimated to witness a CAGR of around 1.7% over the forecast period.

In terms of applications, the pain relief segment held the largest market share in 2015 with a revenue generation of over 9.3 billion. The extensive amount of pain caused during chemotherapy and radiotherapy are the primary factors resulting in the increasing incorporation of these drugs in the cancer segment.

The post-operative pain management segment is expected to be the fastest growing application in the pain relief category.As a result of their high applicability in post- surgical pain management, the rise in number of surgical procedures is expected to fuel the sectorpenetration of opioids in the near future.

The U.S. region dominated the global Opioid Market with a sizable revenue share in 2015. One of the major determinants is the growing geriatric population with clinically demonstrated susceptibility to terminal conditions, such as rheumatoid arthritis, is positively impacting this vertical.

In addition, the increasing adoption of opioids for pain management related to trauma and injury cases, in severe and chronic disabling diseases, and in cases of post-surgical pain, is driving the growth of the market in the North America region

The Canada regional verticalis expected to witnesssignificant growth over the forecast period with a CAGR of over 5.3% due tothe improvinghealthcare infrastructure and the presence of favorable government reforms governing the use of narcoticsin the treatment of both, acute and chronic pain, as well as in the cases of persistent cough and diarrhea. Additionally, the expanding generic drugs market in this region is expected to provide a potential growth platform for the key players in this vertical.

Some of the leadingplayers in this verticalinclude Pfizer, Inc., Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., Allergan Plc (Actavis), and Egalet Corporation. Extensive research and development endeavors carried out by companies with the aim of expanding their product pipeline are expected to boost the growth of this sector.

Browse more reports of this category by Grand View Research: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the North America opioids market on the basis of product, application,and region:

North America Opioid Market, product outlook by revenue (USD Million, 2014–2024)

Immediate — release / Short — acting Opioids

Codeine

Oxycodone

Hydrocodone

Fentanyl

Morphine

Hydroxymorphone

Oxymorphone

Propoxyphene

Other IR opioids

Extended — release / Long — acting Opioids

Oxycodone

Hydrocodone

Methadone

Fentanyl

Morphine

Oxymorphone

Tapentadol

Buprenorphine

Hydromorphone

Other ER opioids

North America Opioid Market, application outlook by revenue (USD Million, 2014–2024)

Pain Relief

Cancer Pain

Post-operative Pain Management

Low Back Pain

Orthopedic

Neuropathic Pain

Fibromyalgia

Anesthesia

Cough Suppression

Diarrhea suppression

De — addiction

North America market, regional outlook by revenue (USD Million, 2014–2024)

U.S.

Access Press Release By Grand View Research: www.grandviewresearch.com/press-release/north-america-opioid-market-analysis

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com

0 notes

markresearch-blog · 7 years

Text

Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review and Therapeutic Assessment, H2 2017

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2017” to its report offerings. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party source.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297806

Glucagon Like Peptide 2 Receptor (GLP2R) Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition. Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Gastrointestinal, Metabolic Disorders and Toxicology which include indications Short Bowel Syndrome, Chemotherapy Effects, Diabetes, Diarrhea, Gastrointestinal Mucositis, Obesity and Type 2 Diabetes. The latest report Glucagon Like Peptide 2 Receptor (GLP2R) Pipeline Review, H2 2017, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R) - The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects - The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/glucagon-like-peptide-2-receptor-glp2r-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Glucagon Like Peptide 2 Receptor (GLP2R) Overview 6 Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 10 Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutics Assessment 12 Assessment by Mechanism of Action 12 Assessment by Route of Administration 13 Assessment by Molecule Type 15 Glucagon Like Peptide 2 Receptor (GLP2R) Companies Involved in Therapeutics Development 17 Hanmi Pharmaceuticals Co Ltd 17

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297806

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Read Industry News: https://www.industrynewsanalysis.com/

#Receptor #MedicalIndustry #Healthcare #pharmaceutical

0 notes

market-insider · 4 years

Text

North America Opioid Market To Reach $18.5 Billion By 2024

For More Details Please Visit @: http://www.grandviewresearch.com/industry-analysis/north-america-opioid-market

Further key findings from the study suggest:

Grand View Research has segmented the North America opioids market on the basis of product, application,and region:

North America Opioid Market, product outlook by revenue (USD Million, 2014 - 2024)

· Immediate - release / Short - acting Opioids

o Codeine

o Oxycodone

o Hydrocodone

o Fentanyl

o Morphine

o Hydroxymorphone

o Oxymorphone

o Propoxyphene

o Other IR opioids

· Extended - release / Long - acting Opioids

o Oxycodone

o Hydrocodone

o Methadone

o Fentanyl

o Morphine

o Oxymorphone

o Tapentadol

o Buprenorphine

o Hydromorphone

o Other ER opioids

North America Opioid Market, application outlook by revenue (USD Million, 2014 - 2024)

· Pain Relief

o Cancer Pain

o Post-operative Pain Management

o Low Back Pain

o Orthopedic

o Neuropathic Pain

o Fibromyalgia

· Anesthesia

· Cough Suppression

· Diarrhea suppression

· De - addiction

North America market, regional outlook by revenue (USD Million, 2014 - 2024)

· U.S.

#North America Opioid Market #healthcare

0 notes